| Casey Allen Cates, MD | |
|
3409 Worth St, Suite 320, Dallas, TX 75246-2029 | |
| (214) 820-8350 | |
| (214) 820-8355 |
| Full Name | Casey Allen Cates |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 22 Years |
| Location | 3409 Worth St, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497872774 | NPI | - | NPPES |
| N0075G | Medicaid | SC | |
| 178086803 | Medicaid | TX | |
| 14580 | Other | NC | NCBCBS |
| 8BR116 | Other | TX | BCBS |
| 5907347 | Medicaid | NC |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor University Medical Center | Dallas, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healthtexas Provider Network | 1355254210 | 1810 |
News Archive
State policies have a significant impact on the services performed by substance abuse treatment programs, and could play a key role in efforts to expand the use of research-based "comprehensive" treatment approaches, reports a study in the June issue of the Journal of Substance Abuse Treatment (JSAT).
In a study that included nearly 6 million Medicare Advantage and Medicare fee-for-service beneficiaries from 12 states, rates of angiography and percutaneous coronary interventions were significantly lower among Medicare Advantage beneficiaries and geographic variation in procedure rates was substantial for both payment types, according to a study in the July 10 issue of JAMA.
Pacific Biosciences of California, Inc. today announced that the Board of Patent Appeals and Interferences of the United States Patent and Trademark Office (USPTO) has rendered a decision in a previously announced patent interference provoked by Pacific Biosciences related to single molecule sequencing. The decision cancels all patent claims by Life Technologies Corporation involved in the interference.
Thermo Fisher Scientific Inc., the world leader in serving science, recently mobilized its Food Safety Response Center (FSRC) to develop a method to test for the presence of the veterinary drug phenylbutazone in horsemeat. Phenylbutazone, also known as "bute," is a potent painkiller banned in any horsemeat intended for human consumption.
Major depressive disorder (MDD) impacts 15 million Americans and is the leading cause of disability, yet current treatments possess limited efficacy.
› Verified 9 days ago
| Entity Name | Healthtexas Provider Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760488936 PECOS PAC ID: 1355254210 Enrollment ID: O20040727001187 |
News Archive
State policies have a significant impact on the services performed by substance abuse treatment programs, and could play a key role in efforts to expand the use of research-based "comprehensive" treatment approaches, reports a study in the June issue of the Journal of Substance Abuse Treatment (JSAT).
In a study that included nearly 6 million Medicare Advantage and Medicare fee-for-service beneficiaries from 12 states, rates of angiography and percutaneous coronary interventions were significantly lower among Medicare Advantage beneficiaries and geographic variation in procedure rates was substantial for both payment types, according to a study in the July 10 issue of JAMA.
Pacific Biosciences of California, Inc. today announced that the Board of Patent Appeals and Interferences of the United States Patent and Trademark Office (USPTO) has rendered a decision in a previously announced patent interference provoked by Pacific Biosciences related to single molecule sequencing. The decision cancels all patent claims by Life Technologies Corporation involved in the interference.
Thermo Fisher Scientific Inc., the world leader in serving science, recently mobilized its Food Safety Response Center (FSRC) to develop a method to test for the presence of the veterinary drug phenylbutazone in horsemeat. Phenylbutazone, also known as "bute," is a potent painkiller banned in any horsemeat intended for human consumption.
Major depressive disorder (MDD) impacts 15 million Americans and is the leading cause of disability, yet current treatments possess limited efficacy.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Casey Allen Cates, MD 3409 Worth St, Suite 320, Dallas, TX 75246-2029 Ph: (214) 820-8350 | Casey Allen Cates, MD 3409 Worth St, Suite 320, Dallas, TX 75246-2029 Ph: (214) 820-8350 |
News Archive
State policies have a significant impact on the services performed by substance abuse treatment programs, and could play a key role in efforts to expand the use of research-based "comprehensive" treatment approaches, reports a study in the June issue of the Journal of Substance Abuse Treatment (JSAT).
In a study that included nearly 6 million Medicare Advantage and Medicare fee-for-service beneficiaries from 12 states, rates of angiography and percutaneous coronary interventions were significantly lower among Medicare Advantage beneficiaries and geographic variation in procedure rates was substantial for both payment types, according to a study in the July 10 issue of JAMA.
Pacific Biosciences of California, Inc. today announced that the Board of Patent Appeals and Interferences of the United States Patent and Trademark Office (USPTO) has rendered a decision in a previously announced patent interference provoked by Pacific Biosciences related to single molecule sequencing. The decision cancels all patent claims by Life Technologies Corporation involved in the interference.
Thermo Fisher Scientific Inc., the world leader in serving science, recently mobilized its Food Safety Response Center (FSRC) to develop a method to test for the presence of the veterinary drug phenylbutazone in horsemeat. Phenylbutazone, also known as "bute," is a potent painkiller banned in any horsemeat intended for human consumption.
Major depressive disorder (MDD) impacts 15 million Americans and is the leading cause of disability, yet current treatments possess limited efficacy.
› Verified 9 days ago
Dr. Christopher Michael Sakowski, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7115 Greenville Ave Ste 310, Dallas, TX 75231 Phone: 214-265-3200 Fax: 214-265-3285 | |
Sumant G Krishnan, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 9301 N Central Expy, Suite 400, Dallas, TX 75231 Phone: 214-220-2468 Fax: 214-397-1555 | |
Jorge Casas, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 12222 N Central Expy, Suite 210, Dallas, TX 75243 Phone: 214-615-1949 Fax: 214-615-1949 | |
Nathan Bruck, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 411 N Washington Ave Ste 7000, Dallas, TX 75246 Phone: 214-823-7090 Fax: 214-823-1644 | |
Dr. Michael Wheeler, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8210 Walnut Hill Ln Ste 130, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-750-8504 | |
Dr. Richard S Levy, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 6901 Snider Plz, Ste 200, Dallas, TX 75205 Phone: 214-369-7733 Fax: 214-360-9604 | |
Dr. Robert Russell Scheinberg, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8210 Walnut Hill Ln, Ste 130, Lb 11, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-739-5029 |